文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

洛哌丁胺致严重心脏毒性:基于病例系列和已发表文献的毒代动力学与毒效学分析

Loperamide-induced severe cardiotoxicity: a toxicokinetic and toxicodynamic analysis derived from a case series and the published literature.
PubMed 文献 · Clin Toxicol (Phila) · 2025-04-07
一句话结论慢性洛哌丁胺过量患者因药物及代谢物半衰期长,心脏毒性可持续数日;作者认为需入院心电图并持续监测至心电图改变消退。

本文报告两例患者共三次洛哌丁胺相关心脏毒性发作,患者每日服用洛哌丁胺320-400 mg数周至数年后出现头晕、心动过缓、意识丧失、抽搐或室性心动过速。研究获得系列洛哌丁胺及N-去甲基洛哌丁胺浓度及对应心电图间期,并结合既往发表数据进行毒代动力学与毒效学分析。入院洛哌丁胺浓度为5.37-288 μg/L,终末消除半衰期21.3-38.7 h;N-去甲基洛哌丁胺入院浓度87.67-256.34 μg/L,终末消除半衰期31.9-88.9 h。共42个洛哌丁胺和35个N-去甲基洛哌丁胺浓度与心电图配对数据,采用最大效应(Emax)模型推导浓度-反应关系;较低洛哌丁胺浓度即与心电图异常相关,而N-去甲基洛哌丁胺浓度需更高;结合两者及心脏离子通道体外抑制效价的总相对洛哌丁胺浓度在受试者工作特征曲线上预测心脏毒性优于母药或代谢物单独浓度。延长的心电图间期约5天后消退。

要点

  • 慢性洛哌丁胺过量(320-400 mg/日,数周至数年)患者可表现为头晕、心动过缓、意识丧失、抽搐或室性心动过速。
  • 入院洛哌丁胺浓度5.37-288 μg/L,终末消除半衰期21.3-38.7 h;N-去甲基洛哌丁胺浓度87.67-256.34 μg/L,半衰期31.9-88.9 h,故心脏毒性可持续数日。
  • 较低洛哌丁胺浓度即与心电图异常相关,而N-去甲基洛哌丁胺需更高浓度;结合两者及心脏离子通道体外抑制效价的总相对洛哌丁胺浓度预测心脏毒性优于单一浓度。
  • 一例患者入院后第2天和第3天发生室性心动过速;延长的心电图间期约5天后消退。
  • 作者认为洛哌丁胺过量患者需入院心电图并持续监测直至心电图改变消退。

适用人群与场景

  • 慢性洛哌丁胺过量(320-400 mg/日,持续数周至数年)的患者。
  • 本文报告两例患者共三次洛哌丁胺相关心脏毒性发作。

处置流程与药物剂量

  • 作者认为洛哌丁胺过量患者需入院心电图并持续监测直至心电图改变消退。

红旗征与不能漏的情况

  • 头晕、心动过缓、意识丧失、抽搐或室性心动过速。
  • 一例患者入院后第2天和第3天发生室性心动过速。
  • 延长的心电图间期约5天后消退。

研究设计与关键结果

  • 研究类型为病例系列结合已发表文献的毒代动力学与毒效学分析,样本为两例患者共三次发作。
  • 患者每日服用洛哌丁胺320-400 mg数周至数年后出现头晕、心动过缓、意识丧失、抽搐或室性心动过速。
  • 入院洛哌丁胺浓度5.37-288 μg/L,终末消除半衰期21.3-38.7 h。
  • 入院N-去甲基洛哌丁胺浓度87.67-256.34 μg/L,终末消除半衰期31.9-88.9 h。
  • 共42个洛哌丁胺和35个N-去甲基洛哌丁胺浓度与心电图配对数据,采用最大效应(Emax)模型推导浓度-反应关系。
  • 较低洛哌丁胺浓度即与心电图异常相关,而N-去甲基洛哌丁胺需更高浓度。
  • 结合两者及心脏离子通道体外抑制效价的总相对洛哌丁胺浓度在受试者工作特征曲线上预测心脏毒性优于母药或代谢物单独浓度。
  • 延长的心电图间期约5天后消退;一例患者入院后第2天和第3天发生室性心动过速。

证据类型、等级与局限

  • 证据类型:病例系列(两例患者共三次发作)结合已发表文献的毒代动力学与毒效学分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为洛哌丁胺过量患者需入院心电图并持续监测直至心电图改变消退。
  • 慢性洛哌丁胺过量患者因洛哌丁胺及N-去甲基洛哌丁胺半衰期长,心脏毒性可持续数日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Chronic loperamide overdose is associated with cardiotoxicity. We describe the toxicokinetics of loperamide and N-desmethyl loperamide, and their concentration-response relationship on cardiotoxicity in newly described and published cases.

MATERIALS AND METHODS: We obtained serial loperamide and N-desmethyl loperamide concentrations, and corresponding electrocardiographic intervals in three episodes (two patients) of loperamide-related cardiotoxicity. A toxicokinetic and toxicodynamic analysis was undertaken that included data from previous publications to explore the relationship between these variables.

RESULTS: Patients presented with dizziness, bradycardia, loss of consciousness, and jerking or ventricular tachycardia after taking loperamide 320-400 mg/day for weeks or years. In one patient, ventricular tachycardia occurred on days two and three post-admission. Prolonged electrocardiographic intervals resolved after approximately five days. Admission loperamide concentrations were 5.37-288 μg/L and the terminal elimination half-lives were 21.3-38.7 h. Admission N-desmethyl loperamide concentrations were 87.67-256.34 μg/L and the terminal elimination half-life was 31.9-88.9 h. Overall, there were 42 loperamide and 35 N-desmethyl loperamide concentrations with paired electrocardiographic data, and the concentration-response relationship was derived using a maximum effect (Emax) model. Lower loperamide concentrations were associated with electrocardiographic abnormalities, compared to N-desmethyl loperamide concentrations. The total relative loperamide concentration, which combines both concentrations into a single value using in vitro inhibitory potencies at cardiac ion channels, out-performed either parent or metabolite concentrations alone for predicting cardiotoxicity on receiver operating characteristic curves.

DISCUSSION: Loperamide and N-desmethyl loperamide have long elimination half-lives causing prolonged cardiotoxicity. Higher loperamide and N-desmethyl loperamide concentrations are associated with prolonged electrocardiographic intervals.

CONCLUSIONS: Patients with chronic loperamide overdose are at risk of cardiotoxicity that persists for days due to persistent loperamide and N-desmethyl loperamide concentrations. We believe patients with loperamide overdose need an admission electrocardiograph and continuous monitoring until electrocardiographic changes resolve.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Nic Ionmhain Ú, Chiew AL, Tierney M, et al. Loperamide-induced severe cardiotoxicity: a toxicokinetic and toxicodynamic analysis derived from a case series and the published literature. Clin Toxicol (Phila). 2025. PMID: 40192347. doi:10.1080/15563650.2025.2459763

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。